Immune Thrombocytopenia Treatment Market: By Type (Acute, Chronic), By Treatment (Thrombopoietin Receptor Agonists, Corticosteroids, Intravenous Immunoglobulins and Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), and Geography

Immune Thrombocytopenia Treatment Market size was valued at USD3,204.6 million in 2023 and is poised to grow at an 4.8% CAGR from 2024 to 2030. Thrombocytopenia is defined as an abnormally low platelet count in the blood due to the presence of any illness or ailment. Individuals with thrombocytopenia have delayed or no blood clotting. Due to the high prevalence of thrombocytopenia and growing knowledge of treatment alternatives, the global thrombocytopenia treatment market is likely to grow considerably in the near future. Furthermore, rising government support for fast-track approval to discover newer treatments for this disorder, as well as capital investments in the development of new drugs by biotechnology and pharmaceutical companies, are expected to drive growth in the thrombocytopenia treatment market over the coming years. The immune Thrombocytopenia Drug Market is being propelled by the rising prevalence of immune thrombocytopenia worldwide is a significant driver of the ITP drug market. Factors such as aging populations, improved disease awareness and diagnosis, and the growing incidence of autoimmune diseases contribute to the increasing burden of ITP, driving the demand for effective treatments.

According to the National Centre for Biotechnology Information, Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years. The growing prevalence of ITP expands the market opportunity for pharmaceutical companies and other stakeholders involved in the development, manufacturing, and distribution of ITP drugs. A larger patient population translates to increased market potential, driving investment in R&D, marketing, and sales efforts. Pharmaceutical companies may prioritize ITP drug development initiatives to capitalize on the expanding market opportunity presented by the rising prevalence of the condition. However, high treatment costs, limited awareness in low-income regions, and adverse effects of medications are some of the restraints for the immune thrombocytopenia treatment market.

Immune Thrombocytopenia Treatment Market Key Developments:

• In December 2021, Horizon Therapeutics Plc's board of directors and Amgen Inc.'s board of directors agreed on the terms of a cash offer for the Company by Pillartree Limited.
• In December 2020, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., a subsidiary of 3SBio Inc., and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4.